Last reviewed · How we verify
Insulin glargine plus insulin analogues — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Insulin glargine plus insulin analogues (Insulin glargine plus insulin analogues) — IRCCS San Raffaele.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Insulin glargine plus insulin analogues TARGET | Insulin glargine plus insulin analogues | IRCCS San Raffaele | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Insulin glargine plus insulin analogues CI watch — RSS
- Insulin glargine plus insulin analogues CI watch — Atom
- Insulin glargine plus insulin analogues CI watch — JSON
- Insulin glargine plus insulin analogues alone — RSS
Cite this brief
Drug Landscape (2026). Insulin glargine plus insulin analogues — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-glargine-plus-insulin-analogues. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab